Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (301-310 of 377) with videos related to

Pageof 38
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2025
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast CancerFabio Conforti, Valentina Nekljudova, Isabella Sala, et al.
The New England Journal of Medicine|February 9, 2022
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Rebecca Dent, et al.
Geburtshilfe Und Frauenheilkunde|September 14, 2023
Update Breast Cancer 2023 Part 3 - Expert Opinions of Early Stage Breast Cancer TherapiesHans-Christian Kolberg, Andreas D Hartkopf, Tanja N Fehm, et al.
Cancers|October 21, 2020
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with PertuzumabLaura L Michel, Andreas D Hartkopf, Peter A Fasching, et al.
Geburtshilfe Und Frauenheilkunde|December 2, 2020
Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab EmtansineElena Laakmann, Julius Emons, Florin-Andrei Taran, et al.
Cancers|December 23, 2018
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer RegistryMichael P Lux, Naiba Nabieva, Andreas D Hartkopf, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2021
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 statusAlexander Hein, Andreas D Hartkopf, Julius Emons, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2022
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registryVolkmar Müller, Alexander Hein, Andreas D Hartkopf, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT RegistryAndreas D Hartkopf, Christina B Walter, Hans-Christian Kolberg, et al.
The Lancet. Oncology|November 27, 2025
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trialsFabio Conforti, Johannes Holtschmidt, Valentina Nekljudova, et al.
Pageof 38

Showing results (301-310 of 377) with videos related to

Sort By:
Pageof 38
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2025
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast CancerFabio Conforti, Valentina Nekljudova, Isabella Sala, et al.
The New England Journal of Medicine|February 9, 2022
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Rebecca Dent, et al.
Geburtshilfe Und Frauenheilkunde|September 14, 2023
Update Breast Cancer 2023 Part 3 - Expert Opinions of Early Stage Breast Cancer TherapiesHans-Christian Kolberg, Andreas D Hartkopf, Tanja N Fehm, et al.
Cancers|October 21, 2020
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with PertuzumabLaura L Michel, Andreas D Hartkopf, Peter A Fasching, et al.
Geburtshilfe Und Frauenheilkunde|December 2, 2020
Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab EmtansineElena Laakmann, Julius Emons, Florin-Andrei Taran, et al.
Cancers|December 23, 2018
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer RegistryMichael P Lux, Naiba Nabieva, Andreas D Hartkopf, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2021
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 statusAlexander Hein, Andreas D Hartkopf, Julius Emons, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2022
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registryVolkmar Müller, Alexander Hein, Andreas D Hartkopf, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT RegistryAndreas D Hartkopf, Christina B Walter, Hans-Christian Kolberg, et al.
The Lancet. Oncology|November 27, 2025
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trialsFabio Conforti, Johannes Holtschmidt, Valentina Nekljudova, et al.
Pageof 38